Literature DB >> 10722525

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

E J Ernst1, M E Klepser, M A Pfaller.   

Abstract

The postantifungal effect (PAFE) of fluconazole, MK-0991, LY303366, and amphotericin B was determined against isolates of Candida albicans and Cryptococcus neoformans. Concentrations ranging from 0. 125 to 4 times the MIC were tested following exposure to the antifungal for 0.25 to 1 h. Combinations of azole and echinocandin antifungals (MK-0991 and LY303366) were tested against C. neoformans. Fluconazole displayed no measurable PAFE against Candida albicans or Cryptococcus neoformans, either alone or in combination with either echinocandin antifungal. MK-0991, LY303366, and amphotericin B displayed a prolonged PAFE of greater than 12 h against Candida spp. when tested at concentrations above the MIC for the organism and 0 to 2 h when tested at concentrations below the MIC for the organism.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10722525      PMCID： PMC89826          DOI： 10.1128/AAC.44.4.1108-1111.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Growth medium effect on the antifungal activity of LY 303366.

Authors:  M E Klepser; E J Ernst; M E Ernst; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

2.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

Authors:  M E Klepser; E J Wolfe; R N Jones; C H Nightingale; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

Authors:  M E Klepser; E J Ernst; R E Lewis; M E Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.

Authors:  M E Klepser; E J Wolfe; M A Pfaller
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

5.  In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.

Authors:  E J Ernst; M E Klepser; M E Ernst; S A Messer; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1999-02       Impact factor: 2.803

6.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

7.  Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.

Authors:  M E Ernst; M E Klepser; E J Wolfe; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1996 Nov-Dec       Impact factor: 2.803

8.  The postantibiotic effect of antifungal agents against common pathogenic yeasts.

Authors:  J D Turnidge; S Gudmundsson; B Vogelman; W A Craig
Journal:  J Antimicrob Chemother       Date:  1994-07       Impact factor: 5.790

9.  Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes.

Authors:  F Minguez; M L Chiu; J E Lima; R Nique; J Prieto
Journal:  J Antimicrob Chemother       Date:  1994-07       Impact factor: 5.790

10.  Evaluation of endpoints for antifungal susceptibility determinations with LY303366.

Authors:  M E Klepser; E J Ernst; M E Ernst; S A Messer; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191
  10 in total
  59 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 3.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

4.  In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; J Lowther; A Bryskier; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 5.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 6.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

7.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

8.  In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

Authors:  M A Pfaller; R Hollis; B P Goldstein; S Messer; D Diekema; T Henkel
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

9.  Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies.

Authors:  Dakshnamurthy Selvakumar; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

10.  Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.